Regulatory Operations and Enforcement Branch Health Product Compliance Directorate Jeanne Mance Building, 13th Floor 200 Eglantine Driveway Ottawa, Ontario K1A 0K9

November 4, 2022

Joelle Walker Vice-President, Public and Professional Affairs Canadian Pharmacists Association <u>jwalker@pharmacists.ca</u>

SUBJECT: Compounding children's and infant's acetaminophen and ibuprofen during the current drug shortages

Dear Joelle Walker,

This letter is in regards to concerns raised by your Association on the need for a prescription to compound children's and infant's acetaminophen and ibuprofen.

Health Canada is aware that a shortage of children's and infant's acetaminophen and ibuprofen is having a significant impact on Canada's health system. As such, Health Canada does not object to allowing compounding of these products without a prescription but within a patient-healthcare professional relationship, until this shortage resolves. Health Canada recommends that, at the pharmacy level, appropriate documentation is maintained to demonstrate a patient-healthcare professional relationship.

Health Canada's non-objection is based on the understanding that the Provinces and Territories provide appropriate regulatory oversight over compounding of these products within a patient-health care professional context.

Health Canada remains available to meet with the Canadian Pharmacists Association or its members to answer any questions or address any concerns that may arise. Alternatively, you may contact Kim Godard, Director, Health Product Inspection and Licensing with any questions.

Kind regards,

Linsey Hollett

Director General

ZHollett



c.c.:

Kim Godard, Director, Health Product Inspection and Licensing Division, Health Product Compliance Directorate

Stephanie Di Trapani, Director, Drug Shortages Division, Health Product Compliance Directorate Mary Morgan, Director, Health Product Compliance and Risk Management Division, Health Product Compliance Directorate